Kromatid

About:

KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents.

Website: http://kromatid.com

Top Investors: Small Business Innovation Research, BroadOak Capital Partners, First Capital Ventures

Description:

KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents. It's molecular cytogenetic and GeneTracker assays discover, detect, and diagnose the range of disease-causing mutations - including inversions and translocations - in a single test. Based on Directional Genomic Hybridization (dGH), KromaTiD's assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies Co-founders Andrew Ray, Joel Bedford, Michael Cornforth, and Susan M. Bailey headquartered the company in Fort Collins, Colorado in 2007.